Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects: a cross-sectional studyReport as inadecuate




Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects: a cross-sectional study - Download this document for free, or read online. Document in PDF available to download.

BMC Psychiatry

, 11:118

First Online: 26 July 2011Received: 01 August 2010Accepted: 26 July 2011

Abstract

BackgroundAlthough the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle.

MethodsA cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle.

ResultsSeventy-four 22.2% patients were in the metabolic syndrome group, 61 18.3% patients were in the pre-metabolic syndrome group, and 41 12.3% patients were in visceral fat obesity group. Antipsychotic polypharmacy was present in 167 50.0% patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group adjusted odds ratio AOR, 2.348; 95% confidence interval CI, 1.181-4.668, but not with the metabolic syndrome group AOR, 1.269; 95%CI, 0.679-2.371.

ConclusionsThese results suggest that antipsychotic polypharmacy, compared with monotherapy, may be independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for patients- lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy.

Download fulltext PDF



Author: Fuminari Misawa - Keiko Shimizu - Yasuo Fujii - Ryouji Miyata - Fumio Koshiishi - Mihoko Kobayashi - Hirokazu Shida - Yoshi

Source: https://link.springer.com/







Related documents